What happens in a clinical psilocybin therapy session?

A clinical psilocybin session is not simply a drug administration event — it is a carefully structured encounter with the unconscious, bounded by preparation before and integration after, and shaped at every stage by what researchers call "set and setting": the interior disposition of the participant and the exterior conditions of the room, the guides, and the music.

The most influential modern protocol comes from Roland Griffiths and colleagues at Johns Hopkins, whose landmark 2006 study established the basic architecture still in use today. Participants arrived having already spent considerable time — up to eight hours across four meetings — with their session monitors, developing rapport and trust. This preparatory relationship was considered essential: as Griffiths (2006) notes, the meetings reviewed each participant's life history and current circumstances, and monitors explicitly communicated the expectation that the session could increase personal awareness and insight, while carefully avoiding any mention of the specific criteria being used to assess mystical experience. The preparation was therapeutic before the medicine was ever administered.

On session day, participants arrived fasted of heavy food, gave a urine sample to confirm drug-free status, and were encouraged to rest and reflect before ingestion. The dose used — 30 mg per 70 kg of body weight — was selected as a high but safe dose based on earlier research from the 1960s. The session itself lasted approximately eight hours and took place in what Griffiths (2006) describes as "an aesthetic living-room-like environment designed specifically for the study" — not a clinical examination room but a space meant to feel held and human. Two monitors remained present throughout. For most of the session, participants were encouraged to lie on a couch, wear an eye mask to minimize external visual distraction, and listen through headphones to a classical music program that was identical across all sessions. The instruction was consistent: turn attention inward, stay with whatever arises.

When significant fear or anxiety emerged — and it did, in roughly a fifth to a third of participants even under these carefully managed conditions — monitors offered reassurance verbally or through supportive physical contact. Griffiths (2006) reports that 22% of volunteers experienced notable anxiety or transient paranoia, and 31% experienced significant fear at some point during the session, yet no pharmacological intervention was required in any case.

What the session occasions, at its most significant, is what Griffiths and colleagues measured as a mystical-type experience: a sense of unity, sacredness, noetic quality, deeply felt positive mood, transcendence of time and space, and ineffability. Stanislav Grof, whose decades of LSD research preceded the current psilocybin renaissance, described the same territory in terms of the soul's encounter with what he called the perinatal matrices — layers of experience organized around birth, death, and rebirth — and beyond those, transpersonal experiences that open outward to what he called "the grave and constant in human sufferings," a phrase borrowed from Joyce and cited by Campbell (1972) in his account of Grof's findings. The imagery that arises in these states tends to be mythological in register: crucifixion, flood, dissolution, light.

The Jungian reading of this material is worth holding alongside the pharmacological one. Greg Mahr (2020), writing in the Journal of Jungian Scholarly Studies, argues that psilocybin's primary mechanism — suppression of the default mode network — functions as a neurophysiological correlate of what Jung called abbaissement du niveau mental, the depotentiation of the conscious personality. The ego's grip loosens; what had been excluded from awareness becomes available. Mahr (2020) notes that Jung himself acknowledged this function, even while remaining cautious about chemical shortcuts to depth:

The door to the inner world that psychedelic drugs offer may be more important and valuable now than ever before to challenge the dominance that the conscious ego has acquired.

This is the pneumatic logic worth naming here: the session is often framed — by participants, by researchers, and by the culture surrounding psychedelic therapy — as a path to transcendence, unity, the dissolution of the separate self into something larger and more luminous. That framing is not wrong, but it is partial. The mystical experience is real and powerful; that is precisely what makes it available as a bypass. The question depth psychology would press is not whether the experience was genuine but what the soul does with it afterward — whether the dissolution becomes integration or becomes another version of the old "if I am spiritual enough, I will not suffer." The integration session, which Grof (1980) describes as the phase aimed at applying insights to the problems of everyday living, is where that question gets answered.

Stanislav Grof — portrait of the founder of transpersonal psychology and pioneer of psychedelic psychotherapy
abbaissement du niveau mental — Jung's term for the lowering of the threshold of consciousness
individuation — the lifelong process of becoming a more complete self
set and setting — the interior and exterior conditions that shape altered-state experience

Sources Cited

Griffiths, Roland, 2006, Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance
Grof, Stanislav, 1980, LSD Psychotherapy: The Healing Potential of Psychedelic Medicine
Campbell, Joseph, 1972, Myths to Live By
Mahr, Greg, 2020, Psychedelic Drugs and Jungian Therapy